Abstract 337P
Background
T and NK-cell lymphoma represents approximately 10 to 15% of all non-Hodgkin’s lymphoma worldwide. However, the epidemiology of underlying subtypes varies geographically. As such, we aim to investigate disease patterns, patient demographics and survival outcomes in a multiethnic cohort from Singapore.
Methods
We performed a retrospective analysis on various histological subtypes of T and NK-cell lymphoma diagnosed from 2004 to 2022 (n=325) at the National Cancer Centre Singapore. Clinico-demographic data were collated across major ethnic groups (Chinese, Malay and Indian) and pre-defined age groups (<40, 40-65, and >65 years). Overall survival was estimated using the Kaplan-Meier method.
Results
In our study cohort, the median age was 55 years (range, 15-88), with a male predominance (61.2%). Major ethnic groups include Chinese (72.0%), followed by Malays (10.5%) and Indians (4.6%). In terms of age at diagnosis, the majority presented between ages 40 to 65 years (50.8%) in comparison to other age groups (<40 years, 24.0%) and (>65 years, 25.2%). The most common histological subtypes include angioimmunoblastic T-cell lymphoma/peripheral T-cell lymphoma T-follicular helper phenotype (AITL/PTCL-TFH) (38.8%), natural killer/T-cell lymphoma (NKTCL) (17.2%), and peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) (12.6%). In analysis by age groups, AITL/PTCL-TFH was the dominant diagnosis. The next most common diagnosis was NKTCL for patients above 65 years, and was PTCL-NOS in patients under 40 years. Further analysis of ethnic distribution amongst these common subtypes revealed a similar trend, though interestingly, NKTCL was not observed amongst the Indian subgroup. In the whole cohort, the median overall survival was 21.4 years with a 5-year OS of 75.6%. 5-year OS was significantly worse for PTCL-NOS as compared to AITL/PTCL-TFH or NKTCL (62.5% vs 79.2% and 78.5%, respectively; log-rank p=0.0225). Age at diagnosis, disease stage and IPI risk groups were significantly prognostic, but not ethnic groups and sex.
Conclusions
Through this analysis we identified unique demographic and survival patterns in T and NK-cell lymphoma within our local population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Tanoto Foundation Professorship in Medical Oncology New Century Foundation Limited Ling Foundation Singapore Ministry of Health’s National Medical Research Council Research Transition Award (TA21jun-0005) and Large Collaborative Grant (OFLCG18May-0028).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract